The abstract, titled “Double-Blind, Randomized Controlled Trial of Topical 4% Benzocaine Wipes for Management of Premature Ejaculation: Interim Analysis,” was also one of 30 abstracts selected from more than 3,000 to be included in the 2017 AUA Press Conference Program.
PREBOOST® is a new, proprietary OTC male genital desensitizer used for the treatment of PE and is currently available in the US.
“We are honored to present final clinical trial results of PREBOOST® and to be included for the Press Program at this year’s AUA Annual Meeting,” said Mitchell Steiner, MD, President and Chief Executive Officer of
The abstract is based on interim analysis of an independent clinical study conducted by Jed Kaminetsky, M.D., Medical Director at
About Premature Ejaculation (PE):
More information about the
Contact: Kevin Gilbert: 312-366-2633
Press Release Kari Sharp